SAN DIEGO, Feb. 20, 2018 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, today announced that the
Company's SpineTRACK Registry has received the designation of
Qualified Clinical Data Registry (QCDR) by the Centers of Medicare
and Medicaid Services (CMS) for the 2018 Merit-based Incentive
Payment System (MIPS) reporting year. As a result,
SpineTRACK participants can now use the platform to earn Medicare
payment incentives.
The SpineTRACK Registry is a NuVasive-sponsored prospective,
multicenter, observational data collection quality improvement tool
established in 2011. SpineTRACK serves as a comprehensive and
collaborative data collection and quality improvement solution for
spine practices, and is designed to allow surgeons to use real-time
reports to make better treatment decisions, patients to track their
progress to better understand treatment benefits and hospitals to
evaluate outcome variations to aid in providing the highest value
of care.
MIPS is one of two tracks under the Quality Payment Program,
which moves Medicare Part B providers to a performance-based
payment system. MIPS streamlines three historical Medicare
programs—the Physician Quality Reporting System (PQRS), the
Value-based Payment Modifier (VM) Program and the Medicare
Electronic Health Record (EHR) Incentive Program (Meaningful
Use)—into a single payment program.
Comprising four indicators—1) Quality (50%), 2) Improvement
Activities (15%), 3) Advancing Care Information (25%) and 4) Cost
(10%)—each category is weighted and factored into a final score
which can impact Medicare payments by plus or minus 5% in 2020. As
a QCDR, the SpineTRACK Registry is able to support the MIPS Quality
reporting requirements on behalf of eligible providers.
"SpineTRACK is a unique differentiator for NuVasive and is the
longest-running spine outcomes database sponsored by any spine
company," said Matt Link, executive
vice president, strategy, technology and corporate development for
NuVasive. "Since 2011, more than 9,500 patients have been enrolled
in SpineTRACK and numerous peer-reviewed papers have been published
using its data. The QCDR designation helps our customers meet
quality reporting criteria to deliver optimal results and earn
incentives that can grow their practices. This is truly a value-add
that aligns with our focus on systems-based spine
solutions."
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology
innovation, focused on transforming spine surgery and beyond with
minimally disruptive, procedurally-integrated solutions designed to
deliver reproducible and clinically-proven surgical outcomes. The
Company's portfolio includes access instruments, implantable
hardware, biologics, software systems for surgical planning,
navigation and imaging solutions, magnetically adjustable implant
systems for spine and orthopedics, and intraoperative monitoring
service offerings. With $962 million
in revenues (2016), NuVasive has an approximate 2,300 person
workforce in more than 40 countries serving surgeons, hospitals and
patients. For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties which contribute
to the uncertain nature of these statements include, among others,
risks associated with acceptance of the Company's surgical products
and procedures by spine surgeons, development and acceptance of new
products or product enhancements, clinical and statistical
verification of the benefits achieved via the use of NuVasive's
products (including the iGA® platform), the Company's ability to
effectually manage inventory as it continues to release new
products, its ability to recruit and retain management and key
personnel, and the other risks and uncertainties described in
NuVasive's news releases and periodic filings with the Securities
and Exchange Commission. NuVasive's public filings with the
Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date
on which it was made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-spinetrack-registry-named-qualified-clinical-data-registry-by-centers-of-medicare-and-medicaid-services-300601474.html
SOURCE NuVasive, Inc.